Company profile
Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, acquired 2022)
COLL · NASDAQ (BioDelivery Sciences International (formerly NASDAQ: BDSI) was acquired by Collegium Pharmaceutical, Inc. (NASDAQ: COLL) in an all-cash, ~$604M deal that closed March 22, 2022; BDSI no longer trades independently. Resolving to the investor-relevant acquirer; not currently on our roster. Sources: https://clinicaltrials.gov/study/NCT02068027 ; https://api.gleif.org/api/v1/lei-records/529900YQ5QSV2ZNM2W45 ; https://www.globenewswire.com/en/news-release/2022/03/22/2408151/34897/en/Collegium-Completes-the-Acquisition-of-BDSI.html Entity resolved by asset-pipeline-v2.)
Share price · COLL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Mu-opioid receptor and norepinephrine transporter (NET)Small molecule | Diabetic Peripheral Neuropathic Pain |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.